Literature DB >> 8855805

Hypercalcemia due to constitutive activity of the parathyroid hormone (PTH)/PTH-related peptide receptor: comparison with primary hyperparathyroidism.

A M Parfitt1, E Schipani, D S Rao, W Kupin, Z H Han, H Jüppner.   

Abstract

In Jansen's disease (JD), the hypercalcemia found in about half the cases is the result of a mutant, constitutively overactive, form of the PTH/PTHrP receptor, which in these cases also causes the skeletal dysplasia. The subject of the present report was first seen in 1956 and is still under treatment at the same medical center. We report the clinical course and a detailed study of calcium and bone metabolism carried out in 1976 and compare the results with those of six typical patients with mild primary hyperparathyroidism in whom exactly the same studies were carried out. In the patient with JD, the hypercalcemia was of early onset; chronic and nonprogressive; refractory to the administration of phosphate, glucocorticoid, and calcitonin; and accompanied by suppressed PTH levels as determined by two different immunoassays, an undetectable PTHrP level, increased excretion of nephrogenous cAMP (an in vivo bioassay of endogenous PTH production), decreased tubular reabsorption of phosphate, increased tubular reabsorption of calcium, increased biochemical indexes of bone turnover, and increased histological indexes of bone turnover on iliac bone histomorphometry after double tetracycline labeling. There was exaggerated loss of cortical bone and preservation of cancellous bone. All the results in JD relating to renal or skeletal effects of PTH excess were within or close to the ranges found in the hyperparathyroid patients, except that tubular reabsorption of phosphate was more depressed. Because PTH secretion was suppressed, any effects mediated by putative alternative receptors would have been diminished. We conclude that 1) the hypercalcemia due to constitutive overactivity of the PTH/PTHrP receptor is indistinguishable from that of mild primary hyperparathyroidism in clinical characteristics and renal tubular and skeletal features; and 2) the classic laboratory manifestations of primary hyperparathyroidism, with the possible exception of osteitis fibrosa cystica, can all be accounted for by overactivity of a single receptor.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8855805     DOI: 10.1210/jcem.81.10.8855805

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

Review 1.  The PTH/PTHrP receptor in Jansen's metaphyseal chondrodysplasia.

Authors:  L M Calvi; E Schipani
Journal:  J Endocrinol Invest       Date:  2000-09       Impact factor: 4.256

2.  An Inverse Agonist Ligand of the PTH Receptor Partially Rescues Skeletal Defects in a Mouse Model of Jansen's Metaphyseal Chondrodysplasia.

Authors:  Hiroshi Noda; Jun Guo; Ashok Khatri; Thomas Dean; Monica Reyes; Michael Armanini; Daniel J Brooks; Janaina S Martins; Ernestina Schipani; Mary L Bouxsein; Marie B Demay; John T Potts; Harald Jüppner; Thomas J Gardella
Journal:  J Bone Miner Res       Date:  2019-12-04       Impact factor: 6.741

3.  Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone.

Authors:  L M Calvi; N A Sims; J L Hunzelman; M C Knight; A Giovannetti; J M Saxton; H M Kronenberg; R Baron; E Schipani
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

4.  Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling.

Authors:  Minrong Ai; Sheri L Holmen; Wim Van Hul; Bart O Williams; Matthew L Warman
Journal:  Mol Cell Biol       Date:  2005-06       Impact factor: 4.272

5.  Progression of Mineral Ion Abnormalities in Patients With Jansen Metaphyseal Chondrodysplasia.

Authors:  Hiroshi Saito; Hiroshi Noda; Philippe Gatault; Detlef Bockenhauer; Kah Yin Loke; Olaf Hiort; Caroline Silve; Erin Sharwood; Regina Matsunaga Martin; Michael J Dillon; David Gillis; Mark Harris; Sudhaker D Rao; Richard M Pauli; Thomas J Gardella; Harald Jüppner
Journal:  J Clin Endocrinol Metab       Date:  2018-07-01       Impact factor: 5.958

6.  Differential Effect of Renal Cortical and Medullary Interstitial Fluid Calcium on Blood Pressure Regulation in Salt-Sensitive Hypertension.

Authors:  Mildred A Pointer; Shaleka Eley; Lauren Anderson; Brittany Waters; Brittany Royall; Sheena Nichols; Candace Wells
Journal:  Am J Hypertens       Date:  2014-12-31       Impact factor: 2.689

Review 7.  PTH and PTHrP signaling in osteoblasts.

Authors:  Nabanita S Datta; Abdul B Abou-Samra
Journal:  Cell Signal       Date:  2009-02-26       Impact factor: 4.315

8.  Control of bone mass and remodeling by PTH receptor signaling in osteocytes.

Authors:  Charles A O'Brien; Lilian I Plotkin; Carlo Galli; Joseph J Goellner; Arancha R Gortazar; Matthew R Allen; Alexander G Robling; Mary Bouxsein; Ernestina Schipani; Charles H Turner; Robert L Jilka; Robert S Weinstein; Stavros C Manolagas; Teresita Bellido
Journal:  PLoS One       Date:  2008-08-13       Impact factor: 3.240

9.  Modulation of PTH1R signaling by an ECD binding antibody results in inhibition of β-arrestin 2 coupling.

Authors:  Kaushik Sarkar; Lisa Joedicke; Marta Westwood; Rebecca Burnley; Michael Wright; David McMillan; Bernadette Byrne
Journal:  Sci Rep       Date:  2019-10-08       Impact factor: 4.379

Review 10.  Genetic causes of neonatal and infantile hypercalcaemia.

Authors:  Caroline M Gorvin
Journal:  Pediatr Nephrol       Date:  2021-05-14       Impact factor: 3.714

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.